Clinical Trial Search

Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035

Primary: Response Rate — 0.846; 0.786; 0.154; 0.214 proportion of participants

Primary: Occurrence of a Dose-Limiting Toxicity (Phase 1) — 0; 1; 4; 5 Participants

Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants

Primary: Frequency of Dose Limiting Toxicities of Palbociclib — 1; 0 Participants

Primary: Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis) — 7.4; NA months — p=< 0.001

Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants

Primary: Toxicity of Treatment in Terms of Number of Participants With Serious Adverse Events or Adverse Events, Reported — 26 Participants

Primary: Complete Remission — 10 participants

Primary: Number of Subjects With Event-Free Survival in Patients With Newly Diagnosed VHR B-ALL or High-risk Relapse of B-ALL 1 Year After Treatment. — 68.9 percentage of subjects

Primary: Event Free Survival. EFS — 66.0 percentage of participants EFS at 3 yrs3

Primary: The Primary End-point is the Number of Patients in CR After Induction Therapy. — 9 Participants

Primary: Phase I: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 1; 2; 1 participants

Primary: Overall Event-free Survival (EFS) — 87.3 Percentage of Participants

Primary: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) — 0; 0; 12; 2 Participants

Primary: Incidence of Low Dose Daunorubicin Feasbility as Assessed by Absolute Blast Count — 0; 1 Participants

Primary: Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles — 35.6…

Primary: 3-Year Event-Free Survival (EFS) — 68 Participants

Primary: Response Rate — 0; 0; 0 participants

Primary: Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV) — 89.01; 90.53; 78.07; 86.46 percent probability

Primary: the Overall Survival of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial — 1; 0; 0; 0 participants — p=<0.05

Primary: Complete Response (CR) Rate — 28 percentage of participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 69 Participants

Primary: Number of Participants Who Achieved a Morphologic Complete Response Within the First Four Cycles of Lenalidomide Treatment According to the Modified International…

Primary: Number of Patients That Experienced DLT During Cycle 1 of Therapy — 3; 3; 5; 3 Participants

Primary: DFS of Non-DS HR Post-induction Patients Receiving Intrathecal (IT) Methotrexate (MTX) Compared With Patients Receiving Intrathecal Triple Therapy (ITT) on a Modified…

Primary: 3-year Event-free Survival (EFS) Rate — 66.0 Percentage of Participants — p=0.032

Primary: Cohort 1: Percentage of Participants With Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL) — 0 Percentage of participants

Primary: Asparaginase-Related Toxicity Rate — 26; 28 percentage of participants — p=.60

Primary: Event-free Survival (EFS) for SR-Average ALL Patients — 83.82; 88.89; 88.34; 90.51 percent probability